Nextage Therapeutics (XTAE:NXTG) Total Liabilities: ₪32.24 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:NXTG Nextage Therapeutics Ltd XTAE:NXTG
8 GF Score
Price ₪0.39
GF Value ₪0.31
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Nextage Therapeutics Total Liabilities?

Nextage Therapeutics XTAE:NXTG 8 Total Liabilities is ₪32.24 Mil as of Dec. 2025. GuruFocus rates XTAE:NXTG with a GF Score™ of 8/100 and a GF Value™ of ₪0.31 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Nextage Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 was ₪32.24 Mil.

Nextage Therapeutics's quarterly Total Liabilities increased from Dec. 2024 (₪23.53 Mil) to Jun. 2025 (₪26.48 Mil) and increased from Jun. 2025 (₪26.48 Mil) to Dec. 2025 (₪32.24 Mil).

Nextage Therapeutics's annual Total Liabilities increased from Dec. 2023 (₪3.83 Mil) to Dec. 2024 (₪23.53 Mil) and increased from Dec. 2024 (₪23.53 Mil) to Dec. 2025 (₪32.24 Mil).

Nextage Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Nextage Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nextage Therapeutics Total Liabilities Chart

Nextage Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.76 1.94 3.83 23.53 32.24

Nextage Therapeutics Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.83 4.88 23.53 26.48 32.24
XTAE:NXTG
8GF Score
Nextage Therapeutics Ltd XTAE:NXTG
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nextage Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nextage Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=28.723+(3.198+5.8980598183211E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.281+0.036)
=32.24

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=46.139-13.901
=32.24

Nextage Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=28.723+(3.198+5.8980598183211E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.281+0.036)
=32.24

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=46.139-13.901
=32.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₪32.24 Mil mean?
Nextage Therapeutics (XTAE:NXTG) has a Total Liabilities of ₪32.24 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nextage Therapeutics and its competitors.
Is Nextage Therapeutics' Total Liabilities too high?
Nextage Therapeutics' current Total Liabilities is ₪32.24 Mil. Overall, Nextage Therapeutics has a GF Score™ of 8/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nextage Therapeutics' Total Liabilities compare to ZTS and UTHR?
Nextage Therapeutics' Total Liabilities of ₪32.24 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nextage Therapeutics and its competitors. Nextage Therapeutics's current Total Liabilities is ₪32.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nextage Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nextage Therapeutics (XTAE:NXTG) is currently considered Modestly Overvalued. The stock's GF Value™ is ₪0.31, compared to a current price of ₪0.39 — trading 25.8% above its estimated fair value. The current Total Liabilities is ₪32.24 Mil. Nextage Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Nextage Therapeutics (XTAE:NXTG), the current Total Liabilities is ₪32.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nextage Therapeutics (XTAE:NXTG) Overvalued in 2026?

Based on GuruFocus' analysis, Nextage Therapeutics stock appears to be overvalued. The current stock price of ₪0.39 is trading 25.8% above its estimated GF Value™ of ₪0.31. GuruFocus considers Nextage Therapeutics to be Modestly Overvalued.

Key valuation signals for XTAE:NXTG:

  • Total Liabilities: ₪32.24 Mil
  • GF Value™: ₪0.31 vs. price of ₪0.39 (25.8% above fair value)
  • GF Score™: 8/100 with 4 warning signs

No single metric tells the full story. See the XTAE:NXTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nextage Therapeutics Business Description

Address Bio-Light, Kiryat Atidim 7, Entrance 1, 2rd Floor, Tel Aviv, ISR, 61581
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.
8GF Score

Get the complete analysis for XTAE:NXTG

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.39
Price
₪0.31
GF Value